Kampman K M, Volpicelli J R, Alterman A I, Cornish J, O'Brien C P
Department of Psychiatry, University of Pennsylvannia School of Medicine, Philadelphia, 19104, USA.
Am J Psychiatry. 2000 Dec;157(12):2052-4. doi: 10.1176/appi.ajp.157.12.2052.
The study examined the effectiveness of amantadine in reducing cocaine withdrawal symptoms and improving treatment outcome among cocaine-dependent patients in outpatient treatment.
Sixty-one cocaine-dependent subjects participated in a double-blind, placebo-controlled trial of amantadine.
Among subjects with severe cocaine withdrawal symptoms at the start of treatment, those who received amantadine used significantly less cocaine during the trial than did subjects who received placebo. Compared to subjects who received placebo, subjects who received amantadine submitted significantly more benzoylecgonine-negative urine samples and used cocaine on significantly fewer days during the trial.
Amantadine may be an effective treatment for cocaine-dependent patients with severe cocaine withdrawal symptoms.
本研究探讨金刚烷胺在减轻门诊治疗的可卡因依赖患者的可卡因戒断症状及改善治疗效果方面的有效性。
61名可卡因依赖受试者参与了一项关于金刚烷胺的双盲、安慰剂对照试验。
在治疗开始时具有严重可卡因戒断症状的受试者中,接受金刚烷胺治疗的受试者在试验期间使用的可卡因量明显少于接受安慰剂治疗的受试者。与接受安慰剂的受试者相比,接受金刚烷胺治疗的受试者提交的苯甲酰爱康宁阴性尿液样本明显更多,且在试验期间使用可卡因的天数明显更少。
金刚烷胺可能是治疗伴有严重可卡因戒断症状的可卡因依赖患者的有效药物。